| abstract |
The present invention discloses HM-1 as an angiogenesis inhibitor modified with a maleimide group and its application, and belongs to the technical field of polypeptide drugs. In the present invention, an appropriate maleimide group was selected to modify the N-terminus of the angiogenesis inhibitor polypeptide HM-1, and the target of the obtained X1-X90 polypeptide sequence did not change, and at the same time, the polypeptide molecule. Has an extended in vivo half-life, low clearance, reduced immunogenicity and antigenicity, can be used for the prevention and treatment of tumors, various types of inflammation and intraocular angiogenesis, and retains antitumor activity. On the other hand, the plasma concentration at the lesion site increased, which reduced the frequency of administration, and the maleimide group-modified HM-1 was changed from the original twice daily administration to once every 7 days. Be changed. [Selection diagram] None |